LDS/Medical Tests/Solute Carrier Organic Anion Transporter Family, Member 1B1 (SLCO1B1) Genotyping, Statin Sensitivity

Solute Carrier Organic Anion Transporter Family, Member 1B1 (SLCO1B1) Genotyping, Statin Sensitivity

The solute carrier organic anion transporter family member 1B1 (SLCO1B1) gene encodes for a membrane-bound sodium-independent organic anion transporter protein (OATP1B1) that is involved in active cellular influx of many endogenous and xenobiotic compounds. The SLCO1B1 gene is located on the short arm (p) of chromosome 12. OATP1B1-dependent transport is an important step in mediating drug hepatic clearance. The most intensely studied drugs transported by this protein are statins. Statins are widely prescribed for cardiovascular disease (CVD), especially in prevention of arteriosclerosis and other vessel occlusive diseases.

Gene mutation in the SLCO1B1 gene results in a low-functioning protein. This impairs statin clearance and may lead to muscle pain, tenderness or weakness, referred to as myopathy. Certain medications can potently inhibit SLCO1B1, causing clinically significant drug interactions and decreased function similar to deleterious gene mutations. The best known gene mutation is SLCO1B1*5 in which valine at position 174 is replaced by alanine (also written as Val174Ala, c.521T>C, rs41490560 and p.V174A) which is associated with simvastatin transportation and clearance. This variant is strongly associated with simvastatin-induced myopathy (with or without CK elevation), especially with high-dose simvastatin therapy. The c.521T>C mutation occurs in either homozygous or heterozygous form in up to 28% of caucasians and asians and about 8% of africans.

The clinical spectrum of statin-induced myopathy ranges from mild myalgia (common) to life-threatening rhabdomyolysis (rare). The FDA recommends standard daily simvastatin dosage of 80mg. In patients with this gene variation, there are modest increases in myopathy risk even at lower simvastatin doses (40mg daily); if optimal efficacy is not achieved with a lower dose, alternate agents should be considered. Carriers of the c.521 T>C variant should avoid high-dose simvastatin therapy. The alternatives to simvastatin include fluvastatin (which is not affected by the c.521T>C variant), atorvastatin, pitavastatin, rosuvastatin and pravastatin, but at reduced doses. Other drugs that are substrates of SLCO1B1 transporter include enalapril, olmesartan, valsartan, atrasentan, repaglinide, nateglinide, methotrexate and bosentan. However, there is insufficient evidence documenting the impact of the c.521 T>C variant on the systemic exposure and safety profile of these drugs.

Mutations of SLCO1B1 are also associated with Rotor syndrome when mutations of SLCO1B3 are also present.

  • Determining the risk for statin-induced myopathy before beginning therapy, especially for simvastatin
  • Monitor and manage simvastatin doses
  • Evaluation of suspected statin-induced myopathy and related diseases

521T>C TC or Intermediate SLCO1B1Transporter Function.

Decreased SLCO1B1 transporter function. The patient's risk for statin-induced myopathy is intermediate.

521T>C CC or Low SLCO1B1Transporter Function.

Severely decreased SLCO1B1 transporter function. The patient's risk for statin-induced myopathy is high.

521T>C TT or Normal SLCO1B1 transport function) indicates no increased risk for statin-induced myopathy. 

Based on new 2014 guidelines, the FDA recommends against 80mg daily simvastatin dosage. In patients with the C allele at SLCO1B1 rs4149056, there are modest increases in myopathy risk even at lower simvastatin doses (40mg daily); if optimal efficacy is not achieved with a lower dose, alternate agents should be considered.

Drug Substrates

  • Statins: simvastatin, atorvastatin, pitavastatin, rosuvastatin and pravastatin.
  • Other drugs: enalapril, olmesartan, valsartan, atrasentan, repaglinide, nateglinide, methotrexate and bosentan. However, there is insufficient evidence documenting the impact of the 521 T>C variant on the systemic exposure and safety profile of these drugs.
  • Fluvastatin is not affected by the 521 T>C variant and could therefore be considered a suitable alternative.

Inhibitors

  • Inhibitors of SLCO1B1 transporter may alter its activity and result in increased levels of drug substrates similar to gene variations.
  • The most common inhibitors are: gemfibrozil, cyclosporine, clarithromycin, protease inhibitors, simeprevir, boceprevir, telaprevir and elthrombopag.

521T> C TT (Normal SLCO1B1 transport function)

No increased risk for statin-induced myopathy.

Allele Specific Primer Extension (ARMS) by Real-time Polymerase chain reaction (PCR), Next generation sequencing (NGS), Conventional Sequencing.

Whole blood collected in lavender top tube (EDTA) or any anticoagulant collection devices. Other specimens; buccal swab, saliva. 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
Drug toxicity testing if available, other CYP450 Gene Variations (CYP3A4, CYP3A5, CYP2D6, CYPC9, CYPC19, COMT, OPRM1, VKORC1).
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login